A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 447 participants.
Also called NCT06628362
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 447 participants
- Sponsor
- Registry
-
NCT06628362
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Canada, Mexico, New Zealand, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT06628362. Randomized; double masking; primary purpose treatment. Start 2024-11-21 (actual); primary completion 2026-05-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
- Condition
- Overweight or Obese
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Enicepatide
- Lead sponsor
- Carmot Therapeutics, Inc.
- Collaborator
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct06628362- Content hash
0ace7b82133b92940b103adf4c826c57a66d866370fa5e482d0c06d5aafbc3ca